A new investment from the US government will help Sanofi and GlaxoSmithKline plc “significantly” increase capacity to produce their COVID-19 vaccine.
The $2.1bn deal signed with the US Department of Health and Human Services and the Department of Defense “will help...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?